224 related articles for article (PubMed ID: 31622218)
1. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
[TBL] [Abstract][Full Text] [Related]
2. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
3. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
Gupta S; Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2019 Nov; 12(1):103. PubMed ID: 31685032
[TBL] [Abstract][Full Text] [Related]
5. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
6. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
8. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
9. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
11. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
13. Subtype specific biomarkers associated with chemoresistance in epithelial ovarian cancer.
Deo A; Mukherjee S; Rekhi B; Ray P
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S64-S69. PubMed ID: 32108633
[TBL] [Abstract][Full Text] [Related]
14. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
16. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
17. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
18. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
19. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Grisham RN; Iyer G
Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
[TBL] [Abstract][Full Text] [Related]
20. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Grisham RN; Chui MH
Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
